R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 58.71
+0.91 (1.57%)
Nov 5, 2026, 4:00 PM EST
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 5.58 billion as of November 5, 2026. It is the 11,013th most valuable company in the world and the 2,635th biggest in China. Its market cap has decreased by 14.01% in one year.
Market Cap
5.58B
Enterprise Value
3.93B
Revenue
957.42M
Global Rank
Country Rank
#2,635 China
PE Ratio
48.09
ChartMarket Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has increased from 5.40B to 5.58B, an increase of 3.27%. That is a compound annual growth rate of 0.76%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 5, 2026 | 5.58B | -1.56% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Innovita Biological Technology | 6.27B |
| Beijing Hotgen Biotech | 6.08B |
| Zhejiang Ausun Pharmaceutical | 5.92B |
| Hangzhou Biotest Biotech | 5.48B |
| Wuhan Keqian Biology Co.,Ltd | 5.40B |
| PharmaResources (Shanghai) | 5.11B |
| Youcare Pharmaceutical Group | 4.99B |
| Jiangsu Aidea Pharmaceutical Group | 4.92B |